Peterson Katharine 4

What Happened

• Katharine Peterson, Chief Accounting Officer of Acrivon Therapeutics (ACRV), received a derivative award covering 31,900 shares on March 1, 2026. The Form 4 reports a per-share price of $0.00 and a $0 total value for the reported acquisition (transaction code A).

Key Details

• Transaction date: 2026-03-01; filing date: 2026-03-03 (filed within the usual 2-business-day Form 4 window).
• Reported amount: 31,900 shares acquired as a derivative award at $0.00 per share (total $0 reported).
• Shares owned after the transaction: not specified in the filing.
• Footnote: 25% of the shares vest on March 1, 2027; the remaining shares vest in 36 substantially equal monthly installments thereafter, subject to continuous service through each vesting date.
• No 10b5-1 plan, tax-withholding event, or immediate sale was reported in this filing.

Context

• This was an award of derivative securities (e.g., options or restricted units as reported by code A) that vest over time rather than an immediate open-market purchase or sale. Such grants are common for employee compensation and do not by themselves indicate short-term buying or selling by the insider.